Poniard Pharma (PARD) option volume and prices elevated into data
More News related to PARD
- Poniard Pharmaceuticals (PARD) Sells 3.5M Shares for Approx $2.15/Share
- Poniard Announces $7.4 Million Financing
- Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
- Morning Movers 11/18: ABK, CHS, LDK, RDN Higher; ONCY, NANO, EXEL, ADSK, CNQR Lower
- Canaccord Adams downgrades Poniard Pharmaceuticals (PARD) to Hold; Less Attractive Risk/Reward
More News related to FDA
- Maxim Group Initiates Coverage on Golden Green Enterprises (CHOP) with a Buy
- Hilliard Lyons Initiates Coveage on Approach Resources (AREX) with a Buy
- Wells Fargo Transfers Coverage on Intuitive Surgical (ISRG) to a Market Perform; Raises Valuation Range
- Wedbush Initiates Coverage on Coinstar (CSTR) with an Outperform
- Thomas Weisel Starts FARO Tech. (FARO) at Overweight, $24 Price Target
Poniard (Nasdaq: PARD) closed at $7.09. PARD is a biopharmaceutical company focused on development of oncology products. SPEAR Phase three study in small cell lung cancer (SCLC) on PARD's Picoplatin is expected by year end 2009. The study was designed to evaluate picoplatin vs. best supportive care for the treatment of platinum resistant/refractory SCLC. PARD November 7.5 straddle $3.15, December is at $5.95. PARD November option implied volatility is at 272, December is at 296, March is at 198, according to Track Data. Paul Foster
Related Categories
FDAOptions
Stocks Mentioned
-0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
